Publications

This document contains the surveillance case definition for Creutzfeldt-Jakob disease (CJD), which is nationally notifiable within Australia. State and territory health departments use this definition to decide whether to notify us of a case.

This report and accompanying table provide a fortnightly summary on notifications of Australia's nationally notifiable diseases for 8 December 2025 to 4 January 2026.

This report and accompanying table provide a fortnightly summary on notifications of Australia's nationally notifiable diseases for 5 to 18 January 2026.

This report and accompanying table provide a fortnightly summary on notifications of Australia's nationally notifiable diseases for 19 January to 1 February 2026.

This report and accompanying table provide a fortnightly summary on notifications of Australia's nationally notifiable diseases for 24 November to 7 December 2025.

This report compiles data gathered by the Antimicrobial Use and Resistance in Australia (AURA) systems from 2022 to 2024. It is a snapshot of information from hospitals, aged care facilities and the community, and demonstrates the use of surveillance data in safeguarding public health in Australia.

These guidelines for Public Health Units provide nationally consistent guidance on how to respond to syphilis. They are part of a Series of National Guidelines (SoNGs) published by the Communicable Diseases Network Australia (CDNA).

This document contains the surveillance case definition for hepatitis C (newly acquired), which is nationally notifiable within Australia. State and territory health departments use this definition to decide whether to notify us of a case.

This document contains the surveillance case definition for hepatitis C (unspecified active), which is nationally notifiable within Australia. State and territory health departments use this definition to decide whether to notify us of a case.

This document contains the surveillance case definition for hepatitis C (individual aged less than 24 months), which is nationally notifiable within Australia. State and territory health departments use this definition to decide whether to notify us of a case.

This document provides an update on the Nipah Virus Infection (NiV) cases reported in India in 2026, including the public health response in India and relevance to Australia.

This document is the technical supplement to the Australian Respiratory Surveillance Report (ARSR) series. It describes the technical background and considerations to help interpret the ARSR surveillance data reported nationally for COVID-19, influenza and respiratory syncytial virus.

This Australian Respiratory Surveillance Report (ARSR) includes information about acute respiratory illnesses including COVID-19, influenza and respiratory syncytial virus.

This document provides an update on the Nipah Virus Infection (NiV) cases reported in West Bengal State, India, in January 2026, including the public health response in India and relevance to Australia.

This guideline explains what entities or facilities are for the purposes of the Security Sensitive Biological Agents (SSBA) Regulatory Scheme.

SSBA – Guideline 2 – Registered facility reporting requirements

This guideline helps entities, facilities and individuals to interpret the National Health Security Regulations when handling samples from a person or animal affected by a security sensitive biological agent (SSBA).

This guideline explains the difference between the loss, theft or accidental release of a security sensitive biological agent (SSBA). It does not set out legal definitions, but outlines what must happen if an SSBA is lost or stolen or accidentally released during its handling at a facility.

SSBA – Guideline 5 – Reporting to law enforcement or the National Security Hotline

This guideline informs entities and facilities about handling toxins on the List of SSBAs. It covers the reportable quantities for toxins on the list and when to register for a Tier 1 or a Tier 2 SSBA if handling Clostridium botulinum.

This guideline explains to entities, facilities and individuals their obligations for security sensitive biological agents (SSBAs) occurring in the natural environment. These SSBAs are not intended to be regulated under the SSBA Regulatory Scheme.

This guideline is for facilities transporting confirmed or suspected security sensitive biological agents (SSBAs). Both sending and receiving facilities must report the transfer. Use the checklists provided to make sure you’re meeting the requirements.

This guideline outlines the reporting and other general requirements for a non-registered facility that receives a confirmed, or suspected, security sensitive biological agent (SSBA).

This guideline lets facilities know what to expect when scheduled for a monitoring inspection. It includes details about required pre-inspection actions, the inspection process itself, and potential post-inspection actions.

This guideline informs entities and facilities under the Security Sensitive Biological Agents (SSBA) Regulatory Scheme when and how they can allow other regulatory schemes to access secure SSBA areas or sensitive information.